Connect with us

Health

Thailand Develops Anti-Covid-19 Nasal Spray

Avatar of CTN News

Published

on

Thailand Develops Anti-Covid-19 Nasal Spray

The Government of Thailand has announced that an anti-Covid-19 nasal spray developed locally will be available for public use by September 2022.

Prime Minister Prayut Chan-o-cha praised the joint project for developing the anti-covid-19 nasal spray.

Chulalongkorn University, Silpakorn University, Health Systems Research Institute (HSRI), Government Pharmaceutical Organization (GPO), and Siam Bioscience collaborated on the project.
The anti-covid-19 nasal spray will be available to the public for sale in the third quarter, a government spokesperson said.

Dr. Rangsee Patlee, deputy director of GPO, said the Food and Drug Administration had granted a certificate for the production of respiratory care medical supplies, which allowed distribution of the nasal spray solution developed by GPO.

Covid-19 Nasal Spray is Safe

He said the anti-Covid-19 nasal spray is also certified by the International Organisation for Standardisation (ISO) for medical devices.

Having passed ISO requirements for the distribution of medical supplies, Dr. Rangsee guarantees the production of this anti-Covid-19 product is safe and of high quality.

In addition to the nasal spray, Dr. Rachada pointed out that Gen Prayut had also praised the GPO for developing Thailand’s second Covid-19 vaccine, HXP-GPOVac, which is currently undergoing its first and second clinical trials.

The FDA is considering whether it should be approved for use because laboratory results indicate it can ward off the Omicron variant.

Despite the failure of the second trial, the GPO is working on a third trial, which could begin by the middle of 2023.

ChulaCov19, an mRNA-based vaccine developed by the Chula Vaccine Research Centre at Chulalongkorn University and the King Chulalongkorn Memorial Hospital in Bangkok, was also discussed.

Tests have proven its efficiency is comparable to Pfizer and Moderna vaccines.

Currently, ChulaCov19 is undergoing a third clinical trial, and if the FDA approves its use, it should be available to the public by year’s end.

Dr. Rachada said that such developments in biotechnology are evidence of Thai scientists’ potential and the strength of the country’s healthcare system.

Despite the fact that Covid-19 will become endemic, vaccine development is still necessary, she added.

Continue Reading

CTN News App

CTN News App

Recent News

BUY FC 24 COINS

compras monedas fc 24

Volunteering at Soi Dog

Find a Job

Jooble jobs

Free ibomma Movies